Displaying items 141-142 of 142 in total
Lexicon's sotagliflozin may revolutionize HFpEF treatment by targeting adipose tissue, a move that could differentiate it in a crowded market.
A bioengineering firm is tapping deceased donors for bone marrow, promising to end shortages and improve outcomes. Is this the future of transplant medicine?
Get your daily brief delivered to your inbox every morning at 7am
